Begin main content

New at CADTH - November 2018

Last updated: November 12, 2018
Product Line: New at CADTH
Result type: Report


The CADTH Drug Portfolio and Medical Devices Portfolio Information Sessions were held on November 1. The presentations for both sessions are now available online here and here respectively.

Save the date. The 2019 CADTH Symposium is being held in Edmonton, Alberta, from April 14 to 16, 2019. Applications are also now open for travels awards and the CADTH Recognition Awards.


CADTH recently issued the following CADTH Canadian Drug Expert Committee (CDEC) drug reimbursement recommendations:

  • dexamethasone (Ozurdex) for diabetic macular edema
  • ozenoxacin (Ozanex) for the topical treatment of impetigo in patients aged two months and older
  • lumacaftor/ivacaftor (Orkambi) for the treatment of cystic fibrosis in patients six years of age and older who are homozygous for the F508del-CFTR mutation in the cystic fibrosis transmembrane conductance regulator gene
  • tapentadol hydrochloride (Nucynta) for the management of pain severe enough to require daily, continuous, long-term opioid treatment; that is opioid-responsive; and for which alternative treatment options are inadequate
  • bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy), a complete regimen for the treatment of HIV-1 infection in adults with no known substitution associated with resistance to the individual components of TBD (bictegravir/emtricitabine/tenofovir alafenamide).


CADTH recently completed the following reports:

Rapid Response Reports — Drug

Rapid Response Reports — Medical Devices and Systems

Environmental Scan Reports

Horizon Scans

Other Publications


We love hearing how our products and services are influencing health care policies, clinical practices, and patient outcomes. If you have a success story to share, please get in touch with your CADTH Liaison Officer.

CADTH E-Alerts: Subscribe to receive the latest CADTH news, reports, feedback opportunities, and events.